Cellarity aims to move closer to the clinic with its whole-cell drug discovery and development approach, which is a departure from the industry’s dominant target-specific approach, with its latest round of venture capital financing.
Cellarity Takes Broader, Whole-Cell Approach To Drug Discovery
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.
